ASSOCIATION OF HOMOCYSTEINE AND ISCHEMIC STROKE IN PAKISTANI POPULATION: A CASE CONTROL STUDY

MT  SAAD; A MUMTAZ; S AHMED; H HASHIM; A MALIK; FF  JANG

doi:10.54112/bcsrj.v2023i1.258

Authors

MT SAAD Department of Neurology, Federal Govt Polyclinic Hospital Islamabad/NUST, Pakistan
A MUMTAZ Department of Neurology, Chandka Medical College Hospital, Shaheed Mohtarma Benazir Bhutto Medical University Larkana, Pakistan
S AHMED Department of Neurology, Al Noor Specialist Hospital Makkah, Saudi Arabia
H HASHIM Department of Neurology, Fauji Foundation Hospital Rawalpindi, Pakistan
A MALIK Department of Neurology, Sharif Medical and Dental College, Lahore, Pakistan
FF JANG Department of Neurosurgery, Sharif Medical and Dental College, Lahore, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2023i1.258

Keywords:

Biochemical Markers, CVA, Ischemic Stroke, Homocysteine

Abstract

Elevated homocysteine levels have been associated with an increased risk of ischemic stroke in various populations. This study aims to find the association between homocysteine and ischemic stroke in the Pakistani population. The study recruited 100 cases with ischemic stroke and 100 controls without any history of stroke from two tertiary care hospitals in Pakistan. Homocysteine levels were measured in both groups using a chemiluminescent microparticle immunoassay. The mean homocysteine level was significantly higher in cases compared to controls (24.64±7.41 µmol/L vs. 12.02±3.59 µmol/L, p<0.001). Logistic regression analysis revealed that high homocysteine levels were independently associated with an increased risk of ischemic stroke (OR=3.62, 95% CI: 2.02-6.50, p<0.001) after adjusting for potential confounders. This study provides evidence for the association between homocysteine levels and ischemic stroke in the Pakistani population. High homocysteine levels were found to be an independent risk factor for ischemic stroke.

Downloads

Download data is not yet available.

References

Haapaniemi E, Helenius J, Soinne L,Serial measurements of plasma homocysteine levels in early and late phases of ischemic stroke. Eur J Neurol. 2007;14(1):12-7.

Qin X, Huo Y, Langman CB, et al. Folic acid therapy and cardiovascular disease in ESRD or advanced chronic kidney disease: a meta-analysis. Clin J Am Soc Nephrol. 2011;6(3):482-488.

Marti-Carvajal AJ, Solà I, Lathyris D, Salanti G. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev. 2017;8(8):CD006612.

Davidson SS. Neurological .Diseases. In: Boon NA, Colledge NR, Walker BR, editors.Davidsons Principles and Practice of Medicine.20th ed. India: :Elsevier; 2009.p.1363-66.

Wilson KM, McCaw RB, Leo L, et al. Prothrombotic effects of hyperhomocysteinemia and hypercholesterolemia in ApoE-deficient mice. Arterioscler Thromb Vasc Biol. 2007; 27(1): 233-40.

Refsum H, Smith AD, Ueland PM, Nexo E, Clarke R, McPartlin J, et al. Facts and recommendations about total homocysteine determinations: an expert opinion. Clin Chem. 2004;50(1):3-32.

Bønaa KH, Njølstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354(15):1578-1588.

Scholze A, Rinder C, Beige J,et al. Acetylcysteine reduces plasma homocysteine concentration and improves pulse pressure and endothelial function in patients with end-stage renal failure. Circulation. 2004; 109(3): 369-74

Furie KL, Kelly PJ. Homocysteine and stroke. Semin Neurol. 2006; 26(1): 24-32.

Tseng YL, Chang YY, Liu JS, et al. Association of plasma homocysteine concentration with cerebral white matter hyperintensity on magnetic resonance images in stroke patients. J Neurol Sci. 2009; 284(1- 2): 36-9.

Drunat S, Moatti N, Paul JL,et al. Homocysteineinduced decrease in endothelin-1 production is initiated at the extracellular level and involves oxidative products. Eur J Biochem. 2001; 268(20): 5287-94.